Bayer Waits on a Trio of Catalysts: A High-Stakes Biotech Bet, a Drug-Pricing Probe, and the Glyphosate Verdict

Bayer's stock stays quiet amid Supreme Court Roundup ruling, US trade probe, and $2.45B deal. Key decisions could reshape billions in liabilities.

For a company that just signed a potential $2.45 billion ophthalmology deal, filed a patent-infringement lawsuit, and faces a new US trade investigation into German drug-pricing rules, Bayer’s stock has been remarkably quiet. The shares closed at €37.81 on Friday, within a whisker of their 50-day moving average, after grinding 4.36% higher over the previous week. The modest drift up belies a calendar packed with inflection points: a Supreme Court ruling on Roundup liability that could reshape billions in provisions, a Section 301 trade probe aimed at Berlin’s price controls, and the slow burn of a pipeline shift that depends on a Phase II implant yet to reach the market.

A $300 Million Bet on the Retina

Bayer completed its acquisition of Perfuse Therapeutics on June 17, paying $300 million upfront with milestone payments that could lift the total to $2.45 billion. The prize is PER-001, an intravitreal implant in Phase II trials for glaucoma and diabetic retinopathy. The deal deepens Bayer’s ophthalmology arsenal at a time when its core pharma franchise is under pressure from generic erosion in legacy drugs. The strategic rationale is clear: injectable therapies that treat chronic retinal diseases command premium pricing and long treatment durations. But the payout hinges on trial results that are still years away.

Glyphosate: The Clock Ticks Down to a Supreme Court Decision

The legal cloud that has dogged Bayer since its acquisition of Monsanto refuses to lift. On June 17, a federal judge in Missouri returned a key case, King v. Monsanto, back to state court, where a preliminary settlement plan was approved in March. The final fairness hearing is scheduled for July 9. That modest procedural win briefly lifted the stock by nearly 5% in a single session, but the macro picture remains daunting: Bayer carries €9.6 billion in provisions for glyphosate claims alone. The real watershed will be a US Supreme Court ruling expected by the end of June. If the justices limit the scope of state-law liability, Bayer could be spared the worst-case scenario of thousands of additional lawsuits. If not, the €5 billion in litigation outflows forecast for 2026 would hammer free cash flow, muting any relief from a positive verdict.

Washington Turns the Screw on German Drug Prices

A new front opened on June 18 when the Office of the US Trade Representative launched a Section 301 investigation into Germany’s pharmaceutical pricing policies. The probe will examine whether price regulations — which often set reimbursement ceilings below US levels — discriminate against American exports. As Germany’s largest drug manufacturer, Bayer is directly in the crosshairs. The investigation is still in its early stages, but any retaliatory tariffs or restrictions would add a layer of geopolitical risk to an already tangled business profile.

Nubeqa vs. Erleada: A Marketing War Turns Legal

Bayer has also taken the fight to Johnson & Johnson on the commercial side. In February it sued J&J over allegedly misleading advertising for the prostate cancer drug Erleada, which claims a 51% reduction in mortality risk versus Bayer’s Nubeqa. Bayer argues that the figure stems from a flawed retrospective analysis, not controlled clinical trials. A US judge rejected Bayer’s request for a preliminary injunction in April, so the case will proceed through normal litigation. Nubeqa is hardly a minor asset — it generated nearly $2 billion in revenue during the first nine months of 2025 — so the outcome of this dispute matters to the top line.

Analyst Optimism Hinges on Execution

The analyst community remains broadly constructive: seven of ten houses rate Bayer a buy, with a consensus price target of €48.61. Berenberg nudged its target to €40.50 in June. But the math is unforgiving. Even if the Supreme Court rules favorably, the €5 billion in expected litigation cash outflows next year threaten to turn free cash flow deeply negative. The Perfuse deal adds pipeline depth but also near-term R&D spending. The Q2 numbers, due August 4, will give the first look at how the operational side is holding up.

The Next Four Weeks Will Set the Tone

Bayer shares are 43% higher than a year ago, yet still trade 24% below their 52-week high of nearly €50. The stock is essentially marking time — waiting for a Supreme Court decision, a fairness hearing, a trade probe’s first findings, and a quarterly earnings report. Each of those events could amplify the current static or tip the stock decisively one way or the other. For now, Bayer is a study in controlled volatility, balancing a biotech wager, a legal siege, and a regulatory spat that could define its trajectory for the rest of the decade.